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Abstract
Background: Discontinuing medications is a complex decision making process and an important medical practice.
It is a tool in reducing polypharmacy, reducing health system expenditure and improving patient quality of life. Few
studies have looked at how general practitioners (GPs) discontinue a medication, in agreement with the patients,
from a professional perspective. Three research questions were examined in this study: when does medication
discontinuation occur in general practice, how is discontinuing medication handled in the GP’s practice and how
do GPs make decisions about discontinuing medication?
Methods: Twenty four GPs were interviewed using a maximum variation sample strategy. Participant observations
were done in three general practices, for one day each, totalling approximately 30 consultations.
Results: The results show that different discontinuation cues (related to the type of consultation, medical records
and the patient) create situations of dissonance that can lead to the GP considering the option of discontinuation.
We also show that there is a lot of ambiguity in situations of discontinuing and that some GPs trialled
discontinuing as means of generating more information that could be used to deal with the ambiguity.
Conclusions: We conclude that the practice of discontinuation should be conceptualised as a continually
evaluative process and one that requires sustained reflection through a culture of systematically scheduled
check-ups, routinely eliciting the patient’s experience of taking drugs and trialling discontinuation. Some policy
recommendations are offered including supporting GPs with lists or handbooks that directly address
discontinuation and by developing more person centred clinical guidelines that discuss discontinuation more
explicitly.
Background
Discontinuing medication is an important medical prac-
tice for a variety of reasons. It is a tool in reducing harms
from taking drugs (e.g. side effects or drug-drug interac-
tions), polypharmacy, reducing health system expenditure
and improving evidence based medicine by discontinuing
treatments that no longer have any evidence or indication
[1, 2]. These challenges are compounded by an increasing
prevalence of patients with several chronic diseases and
several risk factors in high-income countries. These pa-
tients can easily have 20 indicated or recommended drugs
on a medication list, and the challenge of prioritization
and discontinuing medication, when necessary, becomes
an important one [3]. Patients themselves have indicated
they are interested in having more of their medication
discontinued [4, 5]. There has been a growing interest in
reducing the harms from taking drugs that has mainly fo-
cused on overdiagnosis and ‘the art of not doing’ [6–8].
We suggest that this interest in reducing harms caused by
drugs would benefit from extending its focus to discon-
tinuing medication.
Despite there being a tremendous focus on how to
prescribe medication, there has been very little focus
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on the process of discontinuing medication [9, 10]. Pa-
tients are still being prescribed statins during end of
life or palliative care, despite there being no benefit
and some harm [11, 12]. Quantitative research has
shown that discontinuation can be safe, that discon-
tinuing multiple drugs is feasible and that it benefits
patients and healthcare systems [1, 13, 14]. A feasibil-
ity study among elderly patients found that 4–5 drugs
per patient could be discontinued, that 88 % of pa-
tients reported a global improvement in health and
that only 2 % of patients needed to be restarted [14].
In another trial of discontinuation reductions in mor-
tality, referrals to acute care and drug costs were re-
duced [1]. As a result of this research, there have been
calls for a more proactive approach to discontinuing
medication [15, 16].
However, there has been very little qualitative research
that examines the mechanisms of discontinuing medica-
tion and how it is actually done in practice. Most of the
qualitative research has primarily focused on the patient
[17, 18], despite the general practitioner (GP) being an
important actor. GPs (also known as family physicians)
are the biggest prescribers of medication and are often
those that have, willingly or unwillingly, the overall re-
sponsibility of a patient’s medication [3]. Therefore the
process of discontinuing medication as a medical prac-
tice in primary care needs to be better understood.
Clinical decisions about discontinuation are often made
in situations where the relation between causes and effects
are unclear for individual patients. Such situations can be
described as ambiguous, or a problem of too many inter-
pretations that leaves the GP feeling uncertain about how
to proceed [19]. For example, it may be unclear if the
current treatment has any therapeutic value [20] or it may
be unclear how to apply the clinical guidelines to a specific
patient [3]. Whilst characteristics of ambiguous discontinu-
ing situations have been described, this study is interested
in how GPs respond to such situations as little is currently
known about it.
When viewing discontinuing medication as a process
it is important to understand where it occurs, how it is
organised and the role of ambiguity. Thus the research
questions in this study are:
1. When does medication discontinuation occur in
general practice?
2. How is discontinuing medication handled in the
GP’s practice?
3. How do GPs make decisions about discontinuing
medication?
Throughout the study we use the term ‘discontinuing’
rather than ‘deprescribing’ because it is a richer analytical
description of the process. For example, patients cannot
deprescribe their medication, but they can discontinue their
medication. So even though this study’s focus is the profes-
sional, it is still important to allow for a patient’s agency in
the process.
The case of statins
Statins are an ideal case for examining the practice of dis-
continuing medication. Statins are an institutionally recom-
mended drug [21] and the most prescribed drug in Europe
[22, 23]. It is therefore a drug that affects a large number of
people, even though its usage in primary prevention has
been criticized, and its side effects have been underesti-
mated [24]. Statins are an example of risk reducing medica-
tion that are recommended in guidelines and often given
over long periods of time, and which are difficult for GPs to
discontinue [3, 25]. Guidelines in Denmark recommend a
statin when the patient‘s cholesterol is over 5 millimoles/
litre total cholesterol for persons with previous cardiovascu-
lar events, and this acts as a kind of ‘cut-off ’ for GPs. For
persons without previous cardiovascular events, the
HEART SCORE risk card is one of the main tools used to
decide if they should start a statin. It consists of a colour-
coded chart with the colours of red and yellow and green
to indicate what a person’s risk is and whether they should
be prescribed a statin. Because of how relevant statins are
to many people and because they are a recommended drug
that is difficult for the GP to discontinue, they were chosen
as the case for examining discontinuing medication.
Methods
Two data collection methods were employed in this
study: semi-structured interviews and participant obser-
vations. 24 GPs were selected for interviews using a
sampling strategy of maximum variation [26]. The sam-
pling criteria were length of practice, gender, size of the
practice, industry sponsorship (yes/no) and geographical
region. A summary of informant characteristics is shown
in Table 1. Having surveyed recent qualitative studies of
GPs experiences with medication issues, where sample
sizes varied from 7 to 29 with most of these being focus
group studies [3, 27–29] we considered 24 informants to
be an appropriate sample size for an explorative study
like this [30]. Further, after having performed the inter-
views data-saturation was apparent (although we cannot
completely rule out that that new themes might have
been generated by performing more interviews and
observations).
Interviews were on average one hour, recorded and
transcribed afterwards. A pilot study of five interviews
was done to develop and refine the interview guide. The
interviews began by asking the GPs for recent examples
of discontinuing statins so that they could be as concrete
as possible about their reflections and action. If they
could not give any recent examples, the themes from the
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next part of the interview guide were used. These in-
cluded how the GPs kept themselves up-to-date with
knowledge of prescribing and discontinuing and how
they organised discontinuation in their practice.
Participant observations were done in three general
practices. Each practice was observed for one day, total-
ling approximately 30 consultations. The observation
days were chosen beforehand together with the GP so
that these days were more likely to contain consultations
involving discussions about medication. The GPs in the
observed practices were interviewed beforehand, and in
between consultations the GPs often explained their
thought processes and their considerations of the pre-
ceding consultation. Notes were taken during the obser-
vations, and after the observations supplementary notes
were recorded together with reflections on the observa-
tions of the day [31]. Participant observations generated
data on the process of discontinuation and how it
unfolded over time, and thus it complemented the inter-
view data on the GPs’ reasoning and attitudes on
discontinuation.
The method of analysis used was the Gioia method [32].
Here the data was coded inductively and two levels of data
were developed: first order concepts and second order
themes. The first order concepts generated were the initial
codes and categories that closely reflect the original inform-
ant vernacular. Second order themes were developed by
introducing the theoretical concepts of cues and attention
to the first order concepts, so that analytical similarities and
differences were grouped together and the themes offered a
more theoretical perspective on the data. The study was in-
spired by sensemaking theory, a process based perspective
that focuses on how people create meanings that shape
their actions (and vice versa) [19, 33]. So the focus was on
individuals rather than institutions. During the process of
data collection and analysis, the two concepts of cues and
ambiguity emerged as the most relevant theoretical con-
cepts of sensemaking, and so were introduced to the data
to further refine the findings. In this sense, the theoretical
concepts acted as a ‘sensitising instrument’ that increased
our sensitivity to analytically relevant data that otherwise
may have been missed had if strictly inductive approach
was used [34].
During the analysis we also looked for things that sur-
prised or puzzled us in the data. For example, when GPs
were asked about what prompted them to consider dis-
continuation, they often quickly and easily replied be-
cause of side effects. We could have stopped there and
labelled ‘side-effects’ as cues, but we sensed that the ease
with which they said it hid a lot of the work that had to
go into generating this stable and medically accepted
label ‘side effects’. Hence we wanted to find out more
about how these ‘side effects’ arose as an issue in the
first place and this eventually led to one of the study’s
key themes (of patient and record cues). During the ana-
lytical process, the techniques of negative cases, constant
comparisons and peer debriefing were used to improve
the quality of the analysis [32, 35].
Results
Only four of the GPs stated that they regularly discon-
tinued medication. The majority of the respondents re-
ported that discontinuation was rarely done, and as a
specific practice they did not consider it to be very orga-
nized. As one GP noted:
We have always been bad at discontinuing something
I think. I’ve, you know, been a doctor for 14 years now
and I think that we become better at discontinuing
some of it, but we often talk about that we don’t really
do enough about it [discontinuing]. [GP17; p.3]
This description of discontinuing medication as some-
thing often talked about, but rarely done, was frequent
among GPs.
Table 1 Characteristics of the informants
ID Years of experience Practice organisation Geographical region
GP 1 25 Group Capital
GP 2 18 Group Capital
GP 3 16 Group Capital
GP 4 17 Solo Capital
GP 5 16 Solo Capital
GP 6 20 Solo Capital
GP 7 15 Group South Denmark
GP 8 15 Group South Denmark
GP 9 9 Solo Zealand
GP 10 24 Group Capital
GP 11 23 Group Capital
GP 12 22 Solo Capital
GP 13 2 Group Capital
GP 14 18 Group Zealand
GP 15 20 Group North Jutland
GP 16 3 Group South Denmark
GP 17 14 Group South Denmark
GP 18 26 Solo Capital
GP 19 0 Group South Denmark
GP 20 18 Group South Denmark
GP 21 18 Group South Denmark
GP 22 15 Group Capital
GP 23 0 Group North Jutland
GP 24 22 Group North Jutland
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There were at least two reasons for why discontinuing
medication was rarely done. First, the routine of pre-
scribing was so strong that a concerted effort is needed
to even raise the possibility of discontinuing medication:
It’s clear that, when discontinuing medication, as soon
as it’s in the system, you don’t stop any medicine,
unless you yourself implement some systems that flag
it up [as an issue to discuss]. [GP20; p.6]
And the GP sometimes forgot to discuss the possibility
of discontinuation with the patients, especially if the pa-
tient did not mention it:
Sometimes you continue without thinking about it. The
patient doesn’t come in and ask [for discontinuation].
They ask for the same medication. And you think they
benefit from it. [GP6; p.4]
Second, it was difficult for the GPs to identify the right
time to discuss discontinuation with the patient:
Because you can say she has been in the clinic for a lot
of other things in between [the first prescription and
the current check up] and you don’t sit and think, her
cholesterol is looking good and therefore I suddenly
want to look 12 years back in the journal to find out if
the original indication was justified or not. [GP23; p.8]
Thus, a mixture of a strong culture of prescribing and
the difficulty of identifying relevant patients for discon-
tinuing medication led to a sense of discontinuing medi-
cation being challenging to do.
The role of cues and dissonance for discontinuing
medication
Although deliberations about discontinuing a patient’s
medication could come about in many different ways, such
deliberations tended to occur more frequently in certain sit-
uations; e.g. consultations that involved a check up (annual
chronic disease check up, cholesterol check up, nursing
home check up) or consultations with new patients (from
another practice). Such situations were characterized by be-
ing more likely to generate what can be called cues of dis-
continuation. A cue of discontinuation is something that
attracts the GP’s attention toward the possibility of discon-
tinuing medication. If enough attention is drawn to the
possibility of discontinuation, then a dissonance situation is
created, where a question mark is put by the necessity of
the prescription.
Patient based cues are cues emerging from the patient
that the GP would not be able to pick up on his/her
own, without the patient. Examples include: a patient
complains over side effects (muscle pain, depression) or
a high drug burden, a patient makes an explicit wish to
stop medication, a patient shows concern over media re-
ports about problems with specific drugs:
I have discussed it as recently as today with a
patient that takes a lot of medicine, who has also
had some different symptoms and she was very tired
of taking so much medicine. She didn’t ask about
statins specifically, to Simvastatin, which she took,
but the idea of reducing her statin was a good thing
for her. Also because she had so many strange things
with her body, that may actually be related to
statins. [GP22; p.1]
Record based cues are data related cues that can be
extracted by the GP without the patient being present.
Examples include blood test results, patients’ age, num-
ber of drugs prescribed, history of CVD. For example,
one GP said:
A healthy woman aged 87 came to me, she’s on a
statin, and she’s changed her GP [to me]. She gets
simvastatin and she has no diabetes, no ischemic
heart disease and a cholesterol score of 5,2 [the
threshold is 5]. [GP10; p.9]
Here a variety of record based cues, accessible from
records independent of the patient, prompt the GP to
consider discontinuing the statin.
Some cues might singlehandedly trigger consider-
ations about discontinuing medication, e.g. patient
changes GP practice, whereas others might act in con-
junction with other cues, e.g. a patient mentions con-
cern about side effects and the GP then looks at the
record and sees no previous history of cardiovascular
disease (Table 2).
Organising the discontinuation of medication
Despite the rarity and difficulty of discontinuing medica-
tion, there were some GPs who attempted to organise
discontinuation more systematically, and they did so in
two ways. The first was to actively schedule check-ups
and monitoring for a variety of their patients with a need
for reviewing their medication situation. GP 9’s strategies
Table 2 Examples of cues that create dissonance
Patient based cues Record based cues
Side effects (muscle pain, depression) High number of drugs
High drug burden No history of CVD
Patient wants to stop Hospital discharge
Patient concerns from media Blood test results will
70+ years of age
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included visits after hospital discharge and planning hos-
pital admissions (when possible):
I mean, when a patient is discharged from the
hospital, then I get a discharge summary and then
within a week I actually visit them. I mean, if I choose
to come within a week, then I’m able to stop most of it
[unnecessary medication] before the home nurse starts
giving it for a long time. So that way I’ve got a grip on
it. And I also think it’s pretty fun. [GP9; p.8]
Here the GP is proactive in identifying the patient’s
medication needs and examining the necessity of any new
prescriptions. No special reimbursement was available to
the GP for this extra work in term of identifying and visit-
ing relevant patients (though new tariffs have since been
introduced for check-ups with vulnerable patients). How-
ever, the GP saw the process as a stimulating professional
challenge, which presumably contributed to his willing-
ness to perform these systematic checks.
The importance of having this routine systematisation
of monitoring was emphasized by another GP:
It has something to do with the routines that we have
[in the practice], where we have a clear agreement
between us, that such and such prescription renewal
MUST come in for a check-up or they get a bit now,
and know that soon in the future they have to come in
for a check-up. This is for select areas, where we know
there are problems. [GP14; p.9]
If a practice does not proactively invite the patient in for
a check-up (and often the responsibility of represcription
lies with the secretary) then it is difficult to identify and
monitor patients that may benefit from discontinuing
medication. This shows the important role of other actors
besides GPs and patients, as well as the level of organisa-
tion needed to systematically consider discontinuation.
Prescriptions are supposed to be renewed every three
to four months in an effort to continually assess the
drug’s relevance for the patient. However, renewing the
represcriptions often occurs without the patient. So des-
pite there being a theoretical control of medications one
GP noted that the reality is not always as such:
They need to, you know, have their prescription
renewed, so you get a hold of them at some point or
another. I mean, people that get statins need to be
checked. In principle they should be checked every
fourth month, I think it says in the guidance, for their
liver function. So they come to the check-up of the sta-
tin… But, I mean there are also a lot that continue to
take them [statins] for years without being checked
[GP24; p.16]
In other words, organising the discontinuation of
medication by scheduling check-ups is necessary, but
not sufficient in itself. It also requires social interaction -
the patient must be there.
The second way of organising discontinuation was to
elicit more explicitly the patient’s experience of taking
the statin, as opposed to relying on the patient to self-
report any important information.
It makes no sense, if you… can’t lift yourself and sit
down, because you’re on a statin. It is incredibly
different how people react, so it is so, so important that
you follow up, especially after you’ve started something,
to see how big a burden it might be. [GP1; p14]
A patient’s negative experience with taking statins was
often an important factor in the GP’s decision to discon-
tinue. However it was often difficult to predict which pa-
tients would suffer from harms when taking statins or
which patients would experience their burden of drug
treatment as ‘too high’. Therefore the patient’s experi-
ence of taking the drug was important information for
the GP after treatment started. A difference between
GPs was observed in how actively the patient’s experi-
ence was elicited. Some GPs preferred to rely on the pa-
tient to schedule their consultations after experiencing
harms, or to report it themselves at check-ups. Other
GPs were more systematic in following up and eliciting
patient’s experience with medication, including the ef-
fects of individual drugs, the overall drug burden and
patient’s fears or concerns about taking a drug.
Responding to ambiguity
Occasionally there were instances where discontinuing
medication was the obvious thing to do and where the
GP would simply discontinue the statin. For example,
one GP had a new patient from another practice and
saw her for a second consultation. She took a lot of
drugs and they had been discussing her experiences with
this. She felt the burden was high, and that there were
side effects from the statins. She had no history of car-
diovascular disease and her cholesterol scores were not
high. The GP commented:
I mean in my world I would discontinue straightaway
and see what happened. She has as I said not had any
infarctions and so on. So it will be an obvious thing for
me to do, to discontinue that. But then she is an easy
case. [GP22; p.3]
As the final sentence indicates, such clear-cut situa-
tions were rare and the majority of decisions around dis-
continuing medication involved responding to some
level of ambiguity.
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A GP elaborates on the challenges of negotiating con-
flicting sources of information and evaluating the effects
of the treatment on the patient:
It is, you know, like a jigsaw puzzle because I actually
think that it is really hard [knowing when it is best to
discontinue], because I’ve taken it up a lot of times
with many different patients, exactly the issue of an
isolated raised cholesterol level, and when you should
begin treatment. And there’s no-one that agrees, is my
sense… it’s a personal call, and yeah, we know about
all that risk stuff, and that it is not completely OK [to
use SCORE risk charts for persons over 65] … but we
don’t have anything better and… [sigh].. I just think it’s
hard. I don’t think it’s as black and white [as guide-
lines say], because who says that that is a good solu-
tion for the individual patient? [GP19; p.13]
For the GP, the lack of agreement and conflicting
information about when to prescribe or discontinue
the drug, made it hard to decide with confidence what
was most appropriate for the patient. The GP noted
that tools like the SCORE heart risk colour chart was
often used to reduce the ambiguity with elderly
patients, even though she knew it was not appropriate
for people over 65. For the GP, these difficulties with
determining the best course of action showed that the
clinical reality was more ambiguous than suggested by
the guidelines.
A common response was to see this ambiguity as a
reason to continue the treatment. Because of the risk of
an adverse event happening after discontinuing medica-
tion, the safer option was to simply continue prescribing,
thinking that it was better to have tried giving treatment
than not giving treatment, if something went wrong.
There was a fear that:
…you overlook something or make a mistake, and so
you’d better do as they say in all the recommendations
[guidelines]. I know so many that… I mean if there is a
guideline, and it says that we are in the yellow field
here, and that treatment should get started, then you
start [prescribing the drug]. I mean in that flowchart
[for cardiovascular risk] it can be yellow or red. If you
are in the yellow field, then you start [treatment],
because then you at least haven’t done something
wrong. Because if they [the patient] had a blood clot
and you haven’t prescribed anything, then you can’t
[protect yourself and] claim that they were at least
being prescribed [the drug]. [GP19; p.25]
In contrast, there were GPs that saw ambiguity as a
reason trying out discontinuation for a short period
followed by a check-up consultation. One GP elaborated
on the advantages of pausing, rather than discontinuing
straight away:
So I say to the patient, I think we should just have a
break, and making use of a break to see if there are
any changes. But then it means that there is usually a
new decision after the break, you have to decide
whether to continue the drug again or whether it
should be discontinued. So in that way, a break
amounts to two decisions, where discontinuation
demands just one, but that decision is just somewhat
bigger. So a break is a good way to start discontinuing
you could say. [GP20; p.11]
Trialling was a way of practising medication discon-
tinuation without psychologically committing oneself
indefinitely to the process. Rather than one, larger deci-
sion it became two smaller decisions. A pause of one to
6 months generated more information (e.g. does the pa-
tient’s muscle pain disappear or does the cholesterol
level shoot up) and provided an opportunity to revisit
the decision and reflect on its appropriateness. Thus,
trialling allowed GPs to generate more cues if they felt
they had a good reason to consider discontinuation, but
not enough information to be certain. In sum, it was an
acceptable way of trying out discontinuing medication
without being ‘committed’ to the action, because it was
just a ‘trial’.
Discussion
This study contributes to the literature on discontinuing
medication by exploring the perspectives of GPs. Gener-
ally, discontinuing institutionally recommended drugs,
in this case statins, was found to be rare, but there were
some GPs who discontinued systematically, despite the
ambiguity surrounding the outcome. Nearly all instances
of reported discontinuing had elements of dissonance.
Those GPs that discontinued systematically created situ-
ations of dissonance deliberately. In doing so, they cre-
ated a deeper culture of reflecting on the medication
their patients take.
Creating this culture through situations of dissonance
was done in at least two ways. Firstly, by systematically
arranging a variety of different check-up consultations
such as visits after hospital discharges or medication re-
views of elderly home patients. Secondly by actively eli-
citing the patient’s experience of taking drugs, including
the effects of individual drugs, the overall drug burden
and patient’s concerns about taking specific drugs. The
consequence of using both strategies was to produce
more discontinuation cues, which in turn increased the
likelihood of enacting discontinuation. This study com-
plements previous research by showing the importance
of using patient’s experiences in decisions to discontinue
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[20]. The study also shows that discontinuing medica-
tion is more likely to occur when organised proactively,
rather than reactively, e.g. after a patient suffers from
some kind of harm.
The reasons the GPs gave for discontinuing medica-
tion echo the reasons physicians give for abstaining from
guideline recommended drugs [27]. For example the
GPs sometimes choose to discontinue/abstain from
treatment because of concerns about the harms of the
drug, or because of problems with a high burden of
treatment [27, 36]. We suggest that to frame the choice
of GPs to discontinue guideline recommended drugs as
an inability to follow guidelines with negative normative
consequences or as ‘inertia’ is an unproductive one. In-
stead, a more fruitful approach could be to understand
discontinuing medication as clinically relevant care and
to acknowledge and support it as such. As one study on
clinical inertia concluded, ‘much inaction may be clinic-
ally appropriate care’ [37]. Instead of castigating GPs for
a lack of action, more effort should be directed towards
understanding why GPs choose not prescribe a drug or
to discontinue a drug.
Another interesting point from this study is how some
GPs saw ambiguous situations as a reason to act and
trial discontinuing with the patient over a period of time,
rather than a reason not to act. This strategy of trialling
to address the ambiguity of discontinuation has the ef-
fect of producing more cues for the GPs to use in their
decision-making. This supports Weick’s [19] claim that
reducing ambiguity requires access to more varied cues
and the ability to argue for one interpretation over com-
peting alternatives. In the case of discontinuing, GPs can
use the information produced by the trial, e.g. if the
harms disappear or not, to decide together with the pa-
tient if they should confirm or abort the ‘half-decision’
to discontinue.
Our findings suggest that the discontinuation of medi-
cation is a continually evaluative process (e.g. trialling,
restarting at a later date) that depends on the patient’s
situation. This approach is in line with the literature
around situated judgment [9], that decision making
draws on different kinds of justifications and is not
solely determined by the amount of information avail-
able [38]. What these results show is how important it is
that GPs feel more certain about the choice of discon-
tinuing and that they can argue for that choice. So GPs
can never act with complete certainty and discontinuing
will remain an iterative process requiring a variety of
strategies to deal with ambiguity.
Strengths and weaknesses
One of the main strengths of this study is that different
types of data were collected – both interviews and par-
ticipant observations with GPs were used in the analysis.
This allowed for themes to be more comprehensively de-
veloped and crosschecked. For example, the retrospect-
ive accounts of interviews were compensated for by the
current accounts of participant observations. The second
strength of the study is the explicit focus on GP reflec-
tions towards discontinuing medication. Very few stud-
ies have investigated GP attitudes to discontinuation and
currently only one has explicitly done so [3], so this
study offers novel insights into the professional process
of discontinuing medication.
The study also has some weaknesses. Only one drug,
statins, was examined, and it is an example of a risk-
reducing drug that is prescribed on the basis of risk, and
not symptoms. Future research could focus on discon-
tinuing symptomatic medicine, including addictive drugs
like SSRIs for depression, as issues may be different for
those drugs. The study setting was in Denmark, and the
findings may apply differently to different countries, es-
pecially those without general practitioners in a primary
health care system, e.g. the USA. Finally we note two
weaknesses regarding our data collection. The partici-
pant observation data could have been strengthened by
observing all of the practices of the interviewed GPs,
and not just three practices (accounting for 5 of the GPs
interviewed). This would have allowed a more extensive
data analysis. Second, the participants were informed of
the study focus on discontinuation beforehand. This was
done so that they could bring stories of discontinuation
to the interview (a pilot showed that it was difficult for
them to spontaneously relate such stories) and suggest
relevant patient consultations to be observed. Thus it is
possible that the participants may have overstated their
interest and competences concerning the topic at hand.
However, and contrary to our expectations, the GPs
were harsher on themselves in interviews than when
they were observed in practice. So there was little evi-
dence of them flattering themselves in their accounts of
discontinuation, even though they were aware of the
study’s topic.
Implications for policy and practice
The results of the study suggest that creating a culture
of reflecting on patients’ medication during consulta-
tions, eliciting patient experiences of taking drugs, and
trialling discontinuation can inform future policy and
practice. Firstly, GPs can be encouraged to systematically
schedule regular check-ups for relevant patients, espe-
cially those patients that cross healthcare sectors, like
hospitals or nursing homes. Examples of such consulta-
tions include regular follow-up visits after hospital dis-
charge for people over 65 or biannual visits to nursing
homes. However, performing one type of consultation,
e.g. medication reviews for people over 65, may be insuf-
ficient in creating a stronger culture of reflecting on
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patients’ medication. Such a culture could be supported
by pro-actively scheduling, with the help of receptionists
[39], a variety of different types of check-ups, so that
GPs can systematically create situations where they are
more likely to consider discontinuing with the patient.
During these consultations, GPs can be encouraged to
systematically elicit patient experience of taking the
drug, e.g. potential harms, fears or a high drug burden,
in order to facilitate shared decision making. The sug-
gestion of supporting GPs in eliciting patient experiences
and preferences is supported in other discontinuing
medication literature [3, 40].
GPs currently try to reduce ambiguity on a small scale
by individually trialling discontinuation. This process of
reducing ambiguity can be supported on a larger scale,
for example, by developing discontinuation lists or hand-
books [41, 42]. One of the difficulties with discontinuing
statins is that they are institutionally recommended in
clinical guidelines, so more information is needed on
how and when to discontinue institutionally recom-
mended drugs [15]. Part of the problem is that guide-
lines tend to focus on diseases and treatment targets,
rather than the person taking the medication [43]. So
developing more person centred guidelines that priori-
tise the person over the disease with dedicated sections
addressing discontinuing medication could support GPs
by better reflecting their clinical realities [25].
Conclusion
The process of discontinuing medication was found to
be a complex and ambiguous process for GPs in general
practice. Discontinuation cues created situations of dis-
sonance between the option of discontinuing or continu-
ing the patient’s medication. If the high level of
ambiguity meant the GP was in doubt about whether to
discontinue or not, the strategy of trialling discontinu-
ation for a period of time to generate more information
before committing to the decision with the patient could
be used. Suggestions for the future policy are centred on
sustained reflection around discontinuing medication, by
systematically flagging it up through a culture of system-
atically scheduled check-ups and generating information
by explicitly and regularly eliciting the patient’s experi-
ence of taking drugs. The usefulness of these options
needs to be explored more thoroughly if discontinuing
medication is to reduce avoidable drug-related harms to
patients and improve their quality of life.
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